| Title |
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, September 2014
|
| DOI | 10.1007/s00262-014-1609-9 |
| Pubmed ID | |
| Authors |
Luana Calabrò, Giovanni Luca Ceresoli, Alessandra di Pietro, Ornella Cutaia, Aldo Morra, Ramy Ibrahim, Michele Maio |
| Abstract |
No second-line treatment significantly prolongs the survival of malignant mesothelioma patients who have a high unmet medical need. Here, we comment on the therapeutic potential of cytotoxic T-lymphocyte-associated protein (CTLA)4-blockade by the anti-CTLA4 monoclonal antibody (mAb) tremelimumab of refractory malignant mesothelioma patients. We also focus on the critical role of an accurate tumor assessment in the course of treatment with immunomodulating mAb. Finally, treatment with potentially effective, second-generation checkpoint(s) inhibiting mAb, as well future combination strategies in this deadly disease, will be discussed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 19% |
| Student > Doctoral Student | 5 | 16% |
| Student > Bachelor | 3 | 9% |
| Other | 3 | 9% |
| Student > Ph. D. Student | 2 | 6% |
| Other | 4 | 13% |
| Unknown | 9 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 38% |
| Nursing and Health Professions | 3 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Immunology and Microbiology | 2 | 6% |
| Other | 1 | 3% |
| Unknown | 10 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2022.
All research outputs
#4,753,146
of 23,575,346 outputs
Outputs from Cancer Immunology, Immunotherapy
#479
of 2,882 outputs
Outputs of similar age
#50,334
of 251,362 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#10
of 30 outputs
Altmetric has tracked 23,575,346 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,882 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 251,362 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.